Jean-Pierre Enguent, Vice President of R&DSS at SEALSQ Corp, filed a Form 4 on September 3, 2026, reporting two transactions in the company's ordinary shares dated September 1 and September 3, 2026.

Key Highlights

  • Option exercise: Enguent exercised an Employee Stock Option Plan right to buy 15,000 ordinary shares on September 1, 2026, at an exercise price of $0.01 per share.
  • Share sale: All 15,000 ordinary shares were sold on September 3, 2026, at a weighted average price of $2.402, with individual sale prices ranging from $2.38 to $2.4253.
  • Post-transaction ownership: Following both transactions, the filing reports 0 ordinary shares directly owned by the reporting person.
  • Trading plan: According to the filing's footnotes, both the option exercise and the sales were effected pursuant to a Rule 10b5-1 trading plan that Enguent adopted on October 13, 2025.
  • Issuer: SEALSQ Corp is listed on NASDAQ:LAES and is described in the filing as the issuer of the ordinary shares involved in these transactions.

SEALSQ Corp Officer Exercises Options and Sells Resulting Shares Under Pre-Established Plan

According to the filing, Jean-Pierre Enguent, identified as Vice President of R&DSS at SEALSQ Corp, reported two sequential transactions. On September 1, 2026, Enguent exercised an Employee Stock Option Plan right to acquire 15,000 ordinary shares at a price of $0.01 per share, using transaction code M. The underlying option carried an expiration date of April 30, 2032, and had become exercisable as of May 1, 2026, according to Table II of the filing.

Two days later, on September 3, 2026, the filing reports that Enguent disposed of all 15,000 ordinary shares via a sale recorded under transaction code S. The reported weighted average sale price was $2.402 per share. The filing's footnotes specify that the shares were sold across multiple transactions at prices ranging from $2.38 to $2.4253, and that full per-price detail is available upon request from SEALSQ Corp, any security holder, or SEC staff. After both transactions settled, the filing records 0 ordinary shares held directly by the reporting person.

The filing notes that both the exercise and the sale were carried out under a Rule 10b5-1 trading plan that Enguent adopted on October 13, 2025. SEALSQ Corp, traded on NASDAQ:LAES, is a technology company whose registered address for this filing is listed as Avenue Louis-Casai 58, Cointrin, Switzerland. The Form 4 was signed by John O'Hara as Attorney-in-Fact on September 3, 2026.

What Was Disclosed

The filing discloses an option exercise of 15,000 ordinary shares at $0.01 per share on September 1, 2026, followed by a sale of those same 15,000 shares at a weighted average price of $2.402 on September 3, 2026, leaving the reporting person with 0 directly held ordinary shares.